Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a key mediator of signs and symptoms in osteoarthritis. We explored the efficacy, safety, and pharmacokinetics of an anti-GM- CSF antibody, otilimab. The study found a non-significant trend towards a reduction in pain and functional impairment.
